scholarly journals Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

2019 ◽  
Vol 9 (1) ◽  
pp. 116-124 ◽  
Author(s):  
Ben Tran ◽  
Jose M. Ruiz‐Morales ◽  
Enrique Gonzalez‐Billalabeitia ◽  
Anna Patrikidou ◽  
Eitan Amir ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Germ Cell ◽  
Cell Cancer ◽  
Germ Cell Tumors ◽  
Germ Cell Cancer ◽  
First Line ◽  
Cancer Group ◽  
Increased Risk ◽  
Line Chemotherapy

Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16058-e16058
Author(s):  
Ben Tran ◽  
Jose Manuel Ruiz Morales ◽  
Enrique González-Billalabeitia ◽  
Eitan Amir ◽  
Christoph Alexander Seidel ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Germ Cell ◽  
Cell Cancer ◽  
Germ Cell Cancer ◽  
Germ Cell Tumours ◽  
Cancer Group ◽  
Increased Risk

scholarly journals BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG)

1999 ◽  
Vol 10 (3) ◽  
pp. 289-294 ◽  
Author(s):  
J.R. Germá-Lluch ◽  
X. Garcia del Muro ◽  
J.M. Tabernero ◽  
M. S´nchez ◽  
J. Aparicio ◽  
...  
Keyword(s):  
Germ Cell ◽  
Poor Prognosis ◽  
Cell Cancer ◽  
Germ Cell Tumors ◽  
Germ Cell Cancer ◽  
Cancer Group ◽  
Alternating Chemotherapy ◽  
Group Experience

Risk factors for thromboembolic events in testicular cancer patients receiving chemotherapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16109-e16109
Author(s):  
K. Shim ◽  
K. R. Potvin ◽  
K. Mills ◽  
F. Whiston ◽  
L. Stitt ◽  
...  
Keyword(s):  
Risk Factors ◽  
Germ Cell ◽  
Cancer Patients ◽  
Cell Cancer ◽  
Germ Cell Tumors ◽  
Retrospective Chart Review ◽  
Germ Cell Cancer ◽  
Thromboembolic Events ◽  
Increased Risk ◽  
Risk Of Hemorrhage

e16109 Background: Cancer patients are at increased risk for thromboembolic events (TTEs), and those receiving chemotherapy are at even greater risk. Clinical experience and the literature have suggested that men receiving cisplatin-based chemotherapy for metastatic germ cell tumors are at particularly high risk. As TTEs can be fatal and treatment is curative, the stakes are high. Despite this, prophylactic anticoagulation (PA) is not routinely used. Methods: All men treated with cisplatin-based chemotherapy for metastatic germ cell cancer at the London Regional Cancer Program from January 1978 to December 2007 were identified from electronic databases. Data including type and timing of TTEs were extracted by retrospective chart review. Multivariable analyses were used to identify predictors of TTEs. Results: 196 eligible patients were identified with median age 31 years (range, 15–75). No patients received PA. Thirty-two TTEs were identified in 29 patients for an overall incidence of 14.8% (95% CI, 9.8–19.8%). The majority of events were deep venous thromboses, and five patients died due to TTE or its complications. Sixteen of the patients with TTE (55.2%) were diagnosed while on treatment (defined as TTE within 6 months of chemotherapy initiation); 8 (27.6%) had their TTE prior to, and 5 (17.2%) after this time period. Age greater than 30 years (OR = 3.02; 95% CI, 1.10–8.33; p = 0.033) and elevated LDH (OR = 1.93; 95% CI, 1.07–3.48; p = 0.029) were independently associated with an increased risk of TTE. If both adverse risk factors were present, the risk of TTE on treatment was 21.7% (95% CI, 9.8–33.7%). If neither were present, the negative predictive value was 97% (95% CI, 92–100%). Conclusions: The overall TTE incidence rate of 14.8% is consistent with prior reports (8.4–19%). The risk of TTE appears greatest during chemotherapy and shortly thereafter, and nearly one in 10 patients in this group had a TTE. These data support the concept of PA for selected patients starting chemotherapy for metastatic germ cell cancer. However, the efficacy of PA and risk of hemorrhage in this group is unknown. In this cohort, patients under 30 with normal LDH were at very low risk for TTE. Confirmation of these findings to help guide the study and optimal use of PA should be pursued. No significant financial relationships to disclose.

scholarly journals Effect of prophylactic anticoagulation on incidence of venous thromboembolism in testicular germ cell tumor patients.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 422-422
Author(s):  
Nikola Hapakova ◽  
Michal Chovanec ◽  
Katarina Rejlekova ◽  
Katarina Kalavska ◽  
Jana Obertova ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumor ◽  
First Line ◽  
Testicular Germ Cell ◽  
Vte Prophylaxis ◽  
Young Males ◽  
Prophylactic Anticoagulation ◽  
Line Chemotherapy

422 Background: Testicular germ cell tumors (GCTs) are among the most common solid tumors in young males. With the availability of highly effective treatment, improving patients’ quality of life has gained more focus in recent years. Venous thromboembolism (VTE), commonly occurring in GCT patients, is associated with increased morbidity and mortality. Prophylactic anticoagulation has been shown to decrease the risk of VTE in cancer patients. In this retrospective study we evaluated the effect of low molecular weight heparin (LMWH) prophylaxis during hospitalization on incidence of VTE and outcome in GCT patients treated with first-line chemotherapy. Methods: Study population included 394 chemotherapy-naive GCT patients treated with first-line chemotherapy at the National Cancer Institute, Bratislava, Slovakia from January 2000 to December 2017. VTE was defined as any venous thrombosis or pulmonary embolism, confirmed by imaging, occurring during first-line chemotherapy. No visceral thromboses were observed. Results: Forty-one out of 394 patients (10.4%) were diagnosed with VTE on initial staging and were excluded from the analysis. Final cohort included 353 patients. LMWH prophylaxis was administered to 104 patients (29.5%), 249 patients (70.5%) did not receive prophylaxis. We observed 14 (4.0%) VTE events. The difference in VTE incidence between patients with and without prophylaxis was not statistically significant (5.8% vs. 3.2% p = 0.37). We have observed a trend to longer overall survival in patients without prophylaxis (HR = 0.61, 95%CI = 0.32-1.13, p = 0.08). Patients with extragonadal GCT receiving VTE prophylaxis had significantly shorter survival compared to patients without prophylaxis (HR = 0.29, 95%CI = 0.08-1.12, p = 0.04). Conclusions: LMWH prophylaxis was not associated with decreased VTE incidence. Moreover, it was associated with shorter survival in extragonadal GCTs. Taking into account these data, LMWH prophylaxis during hospitalization should not be used in GCT patients receiving chemotherapy.

Effect of prophylactic anticoagulation on incidence of venous thromboembolism in testicular germ cell tumor patients

2020 ◽  
Author(s):  
Nikola Hapakova ◽  
Michal Chovanec ◽  
Katarina Rejlekova ◽  
Katarina Kalavska ◽  
Jana Obertova ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Confidence Interval ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Hazard Ratio ◽  
First Line ◽  
Testicular Germ Cell ◽  
Vte Prophylaxis ◽  
Prophylactic Anticoagulation ◽  
Line Chemotherapy

Abstract Background Testicular germ cell tumors (GCTs) are among the most common solid tumors in young males. With the availability of highly effective treatment, improving patients’ quality of life has gained more focus in recent years. Venous thromboembolism (VTE), commonly occurring in GCT patients, is associated with increased morbidity and mortality. Prophylactic anticoagulation has been shown to decrease the risk of VTE in patients with malignancy. The aim of this retrospective study was to evaluate the effect of low molecular weight heparin (LMWH) prophylaxis on incidence of VTE and outcome in GCT patients treated with first-line chemotherapy. Methods Our study population included chemotherapy-naive GCT patients treated with first-line chemotherapy at the National Cancer Institute, Bratislava, Slovakia from January 2000 to December 2017. VTE was defined as any venous thrombosis or pulmonary embolism, confirmed by imaging, occurring during first-line chemotherapy. Patients diagnosed with VTE on initial staging exam were excluded from the study. No visceral thromboses were observed. Results Our cohort included 353 GCT patients. LMWH prophylaxis was administered to 104 patients (29.5%), 249 patients (70.5%) did not receive prophylaxis. We observed 14 (4.0%) VTE events. The difference in VTE incidence between patients with and without prophylaxis was not statistically significant (5.8% vs. 3.2% P = 0.37). We have observed a trend to longer overall survival in patients without prophylaxis (hazard ratio = 0.61, 95% confidence interval = 0.32-1.13, P = 0.08). Patients with extragonadal GCT receiving VTE prophylaxis had significantly shorter survival. (hazard ratio = 0.29, 95% confidence interval = 0.08-1.12, P = 0.04). This effect was most likely driven by higher incidence of treatment related deaths in patients with extragonadal GCT receiving LMWH. ( P = 0.06) Conclusions LMWH prophylaxis was not associated with decreased VTE incidence. Moreover, there was a higher incidence of treatment related deaths in patients with extragonadal tumor location. LMWH prophylaxis during hospitalization should not be used routinely in GCT patients receiving chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document